Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia

Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Apr 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well the RSV vaccine works in patients with certain blood cancers, such as multiple myeloma, lymphoma, and leukemia. Researchers want to find out how the immune system responds to the vaccine by taking blood samples before vaccination and again about a month later. The results will help doctors understand how effective the vaccine is for these patients and whether it can help protect them from RSV infections, which can be serious.

To participate in this study, patients need to be 60 years or older and have been diagnosed with one of the following conditions: multiple myeloma, lymphoma, chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS), or acute leukemia. Patients who have received the RSV vaccine before or have had severe reactions to any vaccine in the past cannot join the study. Those who do participate will have their blood tested at the hospital's lab, and their doctor will explain the results. Additionally, the study will involve follow-up visits over a year to monitor any RSV infections or vaccine-related complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 60 years and older
• • Patients diagnosed with multiple myeloma(MM) or lymphoma or CLL or myelodysplastic syndrome (MDS) or acute leukemia
• Exclusion Criteria:
• • Patients who have been previously vaccinated against RSV
• • Patients who have experienced a severe reaction to any vaccine in the past